179 related articles for article (PubMed ID: 33584800)
1. Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation.
Zhang Z; Jia Y; Xv F; Song LX; Shi L; Guo J; Chang CK
Front Genet; 2020; 11():603956. PubMed ID: 33584800
[TBL] [Abstract][Full Text] [Related]
2. Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Zeng W; Dai H; Yan M; Cai X; Luo H; Ke M; Liu Z
J Immunol Res; 2017; 2017():4302320. PubMed ID: 29124072
[TBL] [Abstract][Full Text] [Related]
3. SPAG6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model.
Luo J; Mu J; Zhang M; Zhao B; Liu L
Leuk Lymphoma; 2021 Sep; 62(9):2242-2252. PubMed ID: 33843428
[TBL] [Abstract][Full Text] [Related]
4. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
5. Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation.
Wang L; Guo X; Guo X; Zhang X; Ren J
Eur J Pharmacol; 2019 Nov; 863():172676. PubMed ID: 31542488
[TBL] [Abstract][Full Text] [Related]
6. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory Effect of Decitabine on Proliferation of MDS-L Cells and Its Mechanism].
Wu D; Zhang Y; Zhao YS; Guo J; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1471-1476. PubMed ID: 29070127
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.
Zhang C; Suo J; Katayama H; Wei Y; Garcia-Manero G; Hanash S
Clin Proteomics; 2016; 13():14. PubMed ID: 27382363
[TBL] [Abstract][Full Text] [Related]
9. [Functional study of hENT1 on SKM-1 cell resistance to decitabine].
Shi W; Wu L; Guo J; Xu F; Chang C; Li X
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):408-12. PubMed ID: 26031529
[TBL] [Abstract][Full Text] [Related]
10. Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes.
Zhang Z; Huang N; Xv F; Zhao S; Guo J; Zhao Y; Chang C
Curr Oncol; 2022 Sep; 29(10):6933-6946. PubMed ID: 36290822
[TBL] [Abstract][Full Text] [Related]
11. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
12. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
[TBL] [Abstract][Full Text] [Related]
13. [Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
Zhao YS; Guo J; Xu F; Wu D; Wu LY; Song LL; Xiao C; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):124-128. PubMed ID: 28279036
[No Abstract] [Full Text] [Related]
14. Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients.
Li M; Li C; Geng S; Chen X; Wu P; Deng C; Chen X; Lu Z; Weng J; Du X
Front Oncol; 2021; 11():628127. PubMed ID: 33869012
[TBL] [Abstract][Full Text] [Related]
15. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Geng S; Yao H; Weng J; Tong J; Huang X; Wu P; Deng C; Li M; Lu Z; Du X
Leuk Res; 2016 May; 44():17-24. PubMed ID: 26991610
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.
Nguyen AN; Hollenbach PW; Richard N; Luna-Moran A; Brady H; Heise C; MacBeth KJ
Lung Cancer (Auckl); 2010; 1():119-140. PubMed ID: 28210112
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
18. The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells.
Shi M; Xu F; Yang X; Bai Y; Niu J; Drokow EK; Chen M; Chen Y; Sun K
Cancer Manag Res; 2019; 11():8229-8238. PubMed ID: 31564981
[TBL] [Abstract][Full Text] [Related]
19. Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.
Ding K; Fu R; Liu H; Nachnani DA; Shao ZH
Oncol Lett; 2016 Apr; 11(4):2347-2352. PubMed ID: 27073478
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of hypermethylation of DLC-1 gene in myelodysplastic syndrome patients and effects of decitabine on DLC-1 gene expression].
Fu HY; Zhou HR; Yan JG; Chen CJ; Shen JZ
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):412-417. PubMed ID: 28219126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
